Session » (1488–1512) SLE – Treatment Poster II
-
Abstract Number: 1488
Association of Glucocorticoid Use with Patient-Reported Outcomes Among Persons with Systemic Lupus Erythematosus
-
Abstract Number: 1489
Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell–related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study
-
Abstract Number: 1490
Early Experience with SGLT2i in Systemic Lupus Erythematosus
-
Abstract Number: 1491
Targeting the Mevalonate Pathway-dependent Protein Geranylgeranylation to Restrict Follicular Helper T Cell Differentiation for the Treatment of Systemic Lupus Erythematosus
-
Abstract Number: 1492
Pre-treatment Differentially Expressed Metagenes Characterize Systemic Lupus Patients Who Subsequently Achieve Clinical Response to Belimumab
-
Abstract Number: 1494
The Effect of Belimumab on Steroid Use in Patients with SLE: Results from a Retrospective Observational Study of Real-World Data from a US Rheumatology Provider Network
-
Abstract Number: 1495
Deep Serological Profiling of SLE Patients Treated with anti-CD19 CAR T Cells
-
Abstract Number: 1496
Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis
-
Abstract Number: 1497
Eltrombopag in SLE-Associated Thrombocytopenia: Treatment Response and Thrombotic Complications
-
Abstract Number: 1498
First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
-
Abstract Number: 1500
Cumulative Infections by Week 52 Among Patients with SLE: A Summary of Data from Placebo-Controlled Belimumab Studies
-
Abstract Number: 1501
Lupus Low Disease Activity State (LLDAS) Achievement with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE
-
Abstract Number: 1502
Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study
-
Abstract Number: 1503
Disease Course and Complement as Predictors of Response to Standard of Care Plus Placebo in Patients with SLE: A Post Hoc Analysis of Dapirolizumab Pegol and Epratuzumab Clinical Trial Data
-
Abstract Number: 1504
Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S
-
Abstract Number: 1505
Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis: Results from the AURORA 1 and AURORA 2 Studies
-
Abstract Number: 1506
Prescribing Patterns in Lupus Nephritis: Analyzing Time from Proteinuria to Prescription of ACE/ARB
-
Abstract Number: 1507
Pharmacodynamic Changes in SLE Relevant Gene Expression Induced by Deucravacitinib in Patients Enrolled in the Phase 2 PAISLEY Trial
-
Abstract Number: 1508
Predicting in Virtual Patients the Efficacy of an Anti IFNa Mab in Cutaneous Lupus Erythematosus
-
Abstract Number: 1509
Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
-
Abstract Number: 1510
Efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in Women with Systemic Lupus Erythematosus (SLE) Receiving Cyclophosphamide (CYC)